

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Investors, LLC</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/14/2021	3. Issuer Name and Ticker or Trading Symbol <u>RAPID MICRO BIOSYSTEMS, INC.</u> [RPID]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B1 Preferred Stock	(1)	(1)	Class A Common Stock	6,999,998	(1)	I	See footnotes ⁽²⁾⁽⁴⁾ (5)(6)
Series C1 Preferred Stock	(1)	(1)	Class A Common Stock	1,334,562	(1)	I	See footnotes ⁽³⁾⁽⁴⁾ (5)(6)

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Investors, LLC</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>Bain Capital Life Sciences Partners, LP</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
--	--	--

Bain Capital Life Sciences Fund, L.P.

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

BCIP Life Sciences Associates, LP

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Schwartz Jeffrey Lawrence

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Koppel Adam

(Last) (First) (Middle)

200 CLARENDON STREET

(Street)

BOSTON MA 02116

(City) (State) (Zip)

Explanation of Responses:

1. Each share of the Issuer's Series B1 Preferred Stock and Series C1 Preferred Stock is convertible, at the option of the holder, into 0.2 of a share of the Issuer's Class A Common Stock and will automatically convert immediately prior to the closing of the Issuer's initial public offering. These securities have no expiration date.
2. Represents 31,750,072 shares of the Issuer's Series B1 Preferred Stock held by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 3,249,929 shares of the Issuer's Series B1 Preferred Stock held by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").
3. Represents 6,053,214 shares of the Issuer's Series C1 Preferred Stock held by BCLS and 619,605 shares of the Issuer's Series C1 Preferred Stock held by BCIPLS.
4. Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
5. Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of its or their pecuniary interest therein.
6. Jeffrey Schwartz is a director of the Issuer.

Remarks:

BAIN CAPITAL LIFE
SCIENCES INVESTORS,
LLC, By: /s/ Jeffrey 07/14/2021
Schwartz, Title: Managing
Director
BAIN CAPITAL LIFE 07/14/2021
SCIENCES PARTNERS,
LP, By: Bain Capital Life

Sciences Investors, LLC,
its general partner, By: /s/
Jeffrey Schwartz, Title:
Managing Director
BAIN CAPITAL LIFE
SCIENCES FUND, L.P.,
By: Bain Capital Life
Sciences Partners, LP, its
general partner, By: Bain 07/14/2021
Capital Life Sciences
Investors, LLC, its general
partner, By: /s/ Jeffrey
Schwartz, Title: Managing
Director
BCIP LIFE SCIENCES
ASSOCIATES, LP, By:
Boylston Coinvestors, 07/14/2021
LLC, its general partner,
By: /s/ Jeffrey Schwartz,
Title: Authorized
Signatory.
/s/ Jeffrey Schwartz 07/14/2021
/s/ Adam Koppel 07/14/2021
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.